Comments on: Generics Grab Big Share Of Medicare Part D: Study http://www.pharmalot.com/2008/06/generics-grab-big-share-of-medicare-part-d-study/ News, Comment and Conversation Fri, 10 Feb 2012 21:09:59 +0000 http://wordpress.org/?v=2.6.2 By: Just A Thought http://www.pharmalot.com/2008/06/generics-grab-big-share-of-medicare-part-d-study/#comment-363127 Just A Thought Mon, 23 Jun 2008 23:42:14 +0000 http://www.pharmalot.com/?p=14260#comment-363127 As I see it, a change in suppliers is a change in suppliers... be it one excipient or a completed medication, either can create problems. My last scrip was written for a generic... no substitutions. When the pharmacy filled it for the branded product they were refused a sale until they fixed it. Heck, I have 3 months worth of the branded stuff sitting right here. I cannot take it. This just wouldn't fly where generics are concerned... "However, the criteria Pfizer used was not requested by the FDA to show bioequivalence and was different from the FDA criteria, according to an FDA spokeswoman. She adds that the FDA was unable to review the study protocols before Pfizer proceeded and the agency doesn’t know why Pfizer chose different acceptance criteria. Nonetheless, the agency did approve the new Dilantin." http://www.pharmalot.com/2008/05/a-new-version-of-dilantin-is-giving-pfizer-fits/ I do appreciate that, in an effort to disprove generics, they are held to a fairly high standard. Double edged sword ain't it? As I see it, a change in suppliers is a change in suppliers… be it one excipient or a completed medication, either can create problems.
My last scrip was written for a generic… no substitutions. When the pharmacy filled it for the branded product they were refused a sale until they fixed it. Heck, I have 3 months worth of the branded stuff sitting right here. I cannot take it.

This just wouldn’t fly where generics are concerned…

“However, the criteria Pfizer used was not requested by the FDA to show bioequivalence and was different from the FDA criteria, according to an FDA spokeswoman. She adds that the FDA was unable to review the study protocols before Pfizer proceeded and the agency doesn’t know why Pfizer chose different acceptance criteria. Nonetheless, the agency did approve the new Dilantin.”
http://www.pharmalot.com/2008/05/a-new-version-of-dilantin-is-giving-pfizer-fits/

I do appreciate that, in an effort to disprove generics, they are held to a fairly high standard.
Double edged sword ain’t it?

]]> By: Bob Freeman http://www.pharmalot.com/2008/06/generics-grab-big-share-of-medicare-part-d-study/#comment-363117 Bob Freeman Mon, 23 Jun 2008 22:49:47 +0000 http://www.pharmalot.com/?p=14260#comment-363117 Perhaps this is why the industry is fighting at the states' level to change mandatory generic substitution laws. It's certainly not a public health issue; simply a way to game the reimbursement system. What the industry doesn't realize is that their ploy, should it become relatively successful, is a natural justification for reference pricing at the therapeutic category or product level. Perhaps this is why the industry is fighting at the states’ level to change mandatory generic substitution laws. It’s certainly not a public health issue; simply a way to game the reimbursement system. What the industry doesn’t realize is that their ploy, should it become relatively successful, is a natural justification for reference pricing at the therapeutic category or product level.

]]> By: Sam http://www.pharmalot.com/2008/06/generics-grab-big-share-of-medicare-part-d-study/#comment-363067 Sam Mon, 23 Jun 2008 19:02:28 +0000 http://www.pharmalot.com/?p=14260#comment-363067 This report is correct, but the vast majority of Plan D insurance companies demand generic use. Even brand drugs maybe rejected with a message from the Plan saying physician should use a 2 step procedure requiring the physician to try a generically available drug used for the same condition. It has been my experience that about 12% of the patients would prefer the brand. Other patients make sure the physician writes "Brand only". Many times the Plan D insurance and other insurances will require a "prior authorization". This mean the physician has to call a telephone number and discuss with a rep from the insurance company as to why the brand drug is necessary. This can mean a 2 to 3 day delay in making the drug available -- If approved! This report is correct, but the vast majority of Plan D insurance
companies demand generic use. Even brand drugs maybe
rejected with a message from the Plan saying physician should
use a 2 step procedure requiring the physician to try a generically
available drug used for the same condition.

It has been my experience that about 12% of the patients would
prefer the brand. Other patients make sure the physician writes
“Brand only”. Many times the Plan D insurance and other insurances
will require a “prior authorization”. This mean the physician has to
call a telephone number and discuss with a rep from the insurance company as to why the brand drug is necessary. This can mean a
2 to 3 day delay in making the drug available — If approved!

]]>